Table 3. . Quality of life assessment completion rates.
| Study | Treatment | QoL assessment completion rates (%) | Ref. | |
|---|---|---|---|---|
| Baseline | During treatment | |||
| LUME-Lung 1 | Docetaxel + placebo Docetaxel + nintedanib |
>85 | ˜80 (during treatment) | [4,17] |
| CheckMate 017 | Nivolumab Docetaxel |
78 77 |
68 (week 12; LCSS) 67 (week 12; LCSS) |
[13,16] |
| BR.21 | Erlotinib Placebo |
93.0 93.8 |
58.4 (at progression) 55.1 (at progression) |
[18,19] |
| JMEI | Docetaxel Pemetrexed |
>80 (based on evaluable patients only) | [20,21] | |
| TITAN | Docetaxel/pemetrexed Erlotinib |
˜90 | ˜80 (during treatment) | [22] |
| TAX-317 | Docetaxel Best supportive care |
75 (baseline and at least on one treatment assessment) 68 (baseline and at least on one treatment assessment) |
[23] | |
LCSS: Lung Cancer Symptom Scale; QoL: Quality of life.